📗 Cite This Artifact
BCL2 (B-Cell Lymphoma 2)
BCL2 (B-Cell Lymphoma 2)
<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">
BCL2 Quick Reference
UniProt ID: [P10415](https://www.uniprot.org/uniprot/P10415)
Gene: [BCL2](/genes/bcl2)
Molecular Weight: 26 kDa
Subcellular Localization: Mitochondrial outer membrane, ER, nuclear envelope
Protein Family: BCL-2 family (anti-apoptotic subfamily)
Key Domains:
- BH4 domain (N-terminal)
- BH3 domain
- BH1 domain
- BH2 domain
- Transmembrane domain (C-terminal)
</div>
Overview
BCL2 (B-Cell Lymphoma 2) is the founding member of the BCL-2 protein family and a central regulator of the intrinsic (mitochondrial) [apoptosis](/entities/apoptosis) pathway[@tsujimoto1984]. As an anti-apoptotic protein, BCL2 protects cells from programmed cell death by preventing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release[@kroemer2000]. In neurodegeneration, BCL2 dysfunction contributes to neuronal vulnerability, while therapeutic strategies aim to enhance BCL2 activity to protect [neurons](/entities/neurons) from apoptosis[@cory2002].
Structure and Domains
BCL-2 Homology (BH) Domains
BCL2 contains four BCL-2 homology domains that mediate protein-protein interactions[@youle2008]:
BCL2 (B-Cell Lymphoma 2)
<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">
BCL2 Quick Reference
UniProt ID: [P10415](https://www.uniprot.org/uniprot/P10415)
Gene: [BCL2](/genes/bcl2)
Molecular Weight: 26 kDa
Subcellular Localization: Mitochondrial outer membrane, ER, nuclear envelope
Protein Family: BCL-2 family (anti-apoptotic subfamily)
Key Domains:
- BH4 domain (N-terminal)
- BH3 domain
- BH1 domain
- BH2 domain
- Transmembrane domain (C-terminal)
</div>
Overview
BCL2 (B-Cell Lymphoma 2) is the founding member of the BCL-2 protein family and a central regulator of the intrinsic (mitochondrial) [apoptosis](/entities/apoptosis) pathway[@tsujimoto1984]. As an anti-apoptotic protein, BCL2 protects cells from programmed cell death by preventing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release[@kroemer2000]. In neurodegeneration, BCL2 dysfunction contributes to neuronal vulnerability, while therapeutic strategies aim to enhance BCL2 activity to protect [neurons](/entities/neurons) from apoptosis[@cory2002].
Structure and Domains
BCL-2 Homology (BH) Domains
BCL2 contains four BCL-2 homology domains that mediate protein-protein interactions[@youle2008]:
| Domain | Residues | Function |
|--------|----------|----------|
| BH4 | 10-30 | Anti-apoptotic function; stabilizes structure |
| BH3 | 93-107 | Pro-apoptotic protein binding groove |
| BH1 | 136-155 | Hydrophobic groove formation |
| BH2 | 187-202 | Completes binding groove |
| TM | 219-239 | Membrane anchoring |
Three-Dimensional Structure
BCL2 adopts a globular fold with[@petros1996]:
- Seven α-helices surrounding a central hydrophobic groove
- The BH3-binding groove accommodates pro-apoptotic partners
- C-terminal transmembrane helix for membrane insertion
Membrane Localization
BCL2 localizes primarily to[@krajewski1997]:
- Mitochondrial outer membrane (primary site)
- Endoplasmic reticulum
- Nuclear envelope
The transmembrane domain anchors BCL2 to these membranes, positioning it to regulate apoptosis.
BCL-2 Family Overview
The BCL-2 family is divided into three functional groups[@czabotar2014]:
Anti-Apoptotic Members
- BCL2, BCL-XL (BCL2L1), MCL1, BCL-W (BCL2L2), BFL1/A1 (BCL2A1), BCL2L13
- Contain all four BH domains
- Protect against apoptosis
Pro-Apoptotic Effectors (BH3-only)
- BAX, BAK, BOK
- Contain BH1-3 domains
- Execute MOMP when activated
BH3-Only Initiators
- BID, BIM (BCL2L11), BAD, NOXA (PMAIP1), PUMA (BBC3), BMF, HRK, BIK
- Contain only BH3 domain
- Sense cellular stress and activate effectors
Normal Function
Apoptosis Regulation
BCL2 inhibits apoptosis through multiple mechanisms[@edlich2011]:
- BCL2 binds BAX/BAK via BH3 groove
- Prevents BAX/BAK oligomerization
- Blocks MOMP
- Traps activators (BIM, tBID)
- Prevents effector activation
- Acts as "sink" for pro-death signals
- Maintains outer membrane integrity
- Prevents cytochrome c release
- Blocks apoptosome formation
Calcium Homeostasis
At the ER, BCL2[@rong1999]:
- Regulates IP3 receptor activity
- Controls calcium release to mitochondria
- Prevents calcium overload-induced apoptosis
Autophagy Regulation
BCL2 binds Beclin-1 (ATG6) and[@pattingre2005]:
- Inhibits [autophagy](/entities/autophagy) initiation
- Releases Beclin-1 under stress
- Coordinates apoptosis and autophagy
Role in Neurodegeneration
Alzheimer's Disease
BCL2 dysregulation in AD includes[@macgibbon1997]:
Findings:
- Decreased BCL2 expression in vulnerable neurons
- Reduced BCL2/BAX ratio (pro-apoptotic shift)
- Altered BCL2 phosphorylation
- BCL2 oxidation impairs function
- Enhanced neuronal susceptibility to [Aβ](/proteins/amyloid-beta) toxicity
- Increased oxidative stress vulnerability
- Accelerated synaptic apoptosis
Parkinson's Disease
In PD, BCL2 plays a protective role[@offen1998]:
Evidence:
- BCL2 overexpression protects dopaminergic neurons
- MPTP toxicity associated with BCL2 downregulation
- BCL2 polymorphisms linked to PD susceptibility
- Reduced BCL2 in substantia nigra
Huntington's Disease
Mutant [huntingtin](/proteins/huntingtin) affects BCL2[@chen2008]:
- Decreases BCL2 transcription via p53
- Promotes BCL2 degradation
- BCL2 overexpression rescues HD models
Stroke and Ischemia
BCL2 is neuroprotective in cerebral ischemia[@martinou1994]:
- BCL2 transgenic mice show reduced infarct size
- BCL2 upregulation correlates with survival
- Delayed neuronal death involves BCL2 loss
ALS
Motor neurons show BCL2 abnormalities[@mu2006]:
- Reduced BCL2 in spinal cord
- Mutant SOD1 decreases BCL2 expression
- BCL2 overexpression extends survival in models
Therapeutic Targeting
BCL2 Enhancement Strategies
| Approach | Agent/Mechanism | Status |
|----------|-----------------|--------|
| Gene therapy | AAV-BCL2 delivery | Preclinical |
| Pharmacologic upregulation | [HDAC](/entities/hdac-enzymes) inhibitors, retinoids | Research stage |
| BH3 mimetics (cancer) | Venetoclax (BCL2 inhibitor) | FDA-approved (cancer); NOT for neurodegeneration |
| Peptide inhibitors | Stapled peptides | Research stage |
BH3 Mimetics: Cancer vs. Neurodegeneration
Important distinction: BH3 mimetics (like venetoclax) INHIBIT BCL2 and are used in cancer to promote tumor cell death. For neurodegeneration, the opposite approach is needed – enhancing BCL2 activity or expression[@ashkenazi2022].
| Context | Strategy | Goal |
|---------|----------|------|
| Cancer | BCL2 inhibition | Kill cancer cells |
| Neurodegeneration | BCL2 enhancement | Protect neurons |
Indirect Approaches
- Growth factors (BDNF, GDNF) upregulate BCL2
- Antioxidants preserve BCL2 function
- Anti-inflammatory agents prevent BCL2 loss
- Exercise increases BCL2 expression
Key Protein Interactions
| Partner | Function | Disease Relevance |
|---------|----------|-------------------|
| BAX | Pro-apoptotic effector | MOMP execution |
| BAK | Pro-apoptotic effector | MOMP execution |
| BIM | BH3-only activator | Stress sensing |
| tBID | Truncated BID | Death receptor pathway |
| BAD | BH3-only sensitizer | Growth factor signaling |
| Beclin-1 | Autophagy regulator | Autophagy inhibition |
| IP3R | Calcium channel | ER calcium regulation |
Regulation
Transcriptional Control
BCL2 transcription is regulated by[@kirsch1999]:
- [NF-κB](/entities/nf-kb) – Pro-survival transcription factor
- CREB – cAMP response element
- p53 – Downregulates BCL2
- STAT3 – Survival signaling
Post-Translational Modifications
| Modification | Site | Effect |
|--------------|------|--------|
| Phosphorylation | Ser70 | Activity regulation |
| Phosphorylation | Thr69 | Reduced function |
| Ubiquitination | Various | Proteasomal degradation |
| Oxidation | Cys residues | Loss of function |
Protein Stability
BCL2 stability is influenced by:
- Proteasome-mediated degradation
- Caspase cleavage during apoptosis
- Oxidative damage
Biomarker Potential
- BCL2/BAX ratio – Indicator of apoptotic susceptibility
- BCL2 expression – In blood cells as surrogate marker
- BCL2 phosphorylation – Activity status readout
Animal Models
BCL2 transgenic mice[@duboisdauphin1994]:
- Neuron-specific overexpression
- Protected from ischemia, excitotoxicity
- Resistance to axotomy-induced death
- Viable but with lymphoid abnormalities
- Increased neuronal vulnerability
- Enhanced sensitivity to toxins
See Also
- [Apoptosis](/mechanisms/apoptosis)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [BAX Protein](/proteins/bax-protein)
- Cytochrome C
- BCL2 Gene
Pathway Diagram
The following diagram shows key molecular relationships for BCL2 (B-Cell Lymphoma 2) based on knowledge graph edges:
Pathway Diagram
The following diagram shows the key molecular relationships involving BCL2 (B-Cell Lymphoma 2) discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | proteins-bcl2 |
| kg_node_id | BCL2 |
| entity_type | protein |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-d0b3878bb8d9 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-bcl2'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-proteins-bcl2?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[BCL2 (B-Cell Lymphoma 2)](http://scidex.ai/artifact/wiki-proteins-bcl2)
http://scidex.ai/artifact/wiki-proteins-bcl2